Schering AG

CINCINNATI, August 11, 2021 /PRNewswire/ -- Blue Water Vaccines, Inc., a biopharmaceutical company, announced today that it has appointed Dr. Ronald R. Cobb as its Head of Science and Discovery. Dr. Cobb brings with him not only exemplary research and development expertise, but also expertise in leading early-stage drug development from the lab to market. His understanding of drug development from inception to supply chain and beyond will be crucial for Blue Water Vaccine's onward journey. "We welcome Ron as an expert strategist with deep knowledge of developing early-stage drugs into successful assets," said Joseph Hernandez, Chairman and CEO of Blue Water Vaccines. "We look forward to him leading Blue Water Vaccines' pipeline initiatives, which focus on treating and preventing pathogen infections." "I am excited to join the growing team at Blue Water Vaccines and to be involved in the critical process of bringing life-saving vaccines to patients globally," noted Dr. Cobb. "Pathogenic infections like Influenza, Streptococcus pneumoniae, and the norovirus are profound global issues that demand effective solutions. As the head of Blue Water Vaccines' scientific initiatives, I plan to propel these ongoing programs forward and establish their clinical path." Dr. Ron Cobb is a geneticist and a molecular biologist with over 25 years of pharmaceutical R&D and manufacturing experience. In his previous roles, Dr. Cobb was responsible for various leadership positions. He was most recently, the Chief Scientific Officer at Ology Bioservices. At Tanabe Research Laboratories, he initiated discovery programs seeking small molecule inhibitors of inflammatory diseases while supporting all internal drug discovery screening efforts with protein expression services. At Berlex Biosciences (U.S. Division of Schering AG) Dr. Cobb led the protein expression division and supported the research and clinical development phase projects. He was also a member of the Scientific Advisory Committee and Worldwide Antibody Development Committee for Schering-Plough Corporation. Dr. Cobb, as principal investigator, has overseen more than $200M in drug development contracts over his career, and has co-authored over 60 peer-reviewed manuscripts. Dr. Cobb earned his BA in Biology from Wake Forest University and his Ph.D. in Biochemistry from the Medical College of Georgia. Blue Water Vaccines is developing a universal influenza vaccine that could potentially provide lifelong protection from influenza, including pandemic strains like the 1918 pandemic and 2009 swine flu. Scientists from the University of Oxford identified epitopes of limited variability in the head domain of the haemagglutinin protein. These epitopes are targeted naturally by the immune system and vaccination studies have shown that regions of influenza viruses that circulated in 2006 and 1977 were able to protect against infection with an influenza virus that last circulated in 1934. About Blue Water Vaccines Blue Water Vaccines, Inc. is a biopharmaceutical company focused on developing transformational vaccines to address significant health challenges globally. Headquartered in Cincinnati, OH, the company holds the rights to proprietary technology developed at the University of Oxford, Cincinnati Children's Hospital Medical Center (CCHMC), and St. Jude Children's Hospital. The company has licensed a novel virus-like particle (VLP) vaccine platform from CCHMC to develop vaccines for multiple infectious diseases. Blue Water Vaccines is developing a Streptococcus pneumoniae (pneumococcus) vaccine candidate, designed to specifically prevent middle ear infections, known as Acute Otitis Media (AOM), in children. The live-attenuated vaccine candidate has been shown to effectively prevent colonization of pneumococcus bacteria in the middle ear of chinchillas regardless of serotype. AOM accounts for approximately 20 million physician visits each year in the United States. Globally, AOM caused by pneumococcus accounts for approximately 300 million cases annually. For more information, visit . Contact Information: Erin Henderson Email: ehenderson@bluewatervaccines.com Olipriya Das (media) Email: olipriya.das@russopartnersllc.com

WHIPPANY, N.J.--( BUSINESS WIRE )--Bayer today announced Nelson Ambrogio as the new Head of the Radiology Business at its Pharmaceuticals Division, effective April 1, 2024. He will report to Stefan Oelrich, Member of the Board of Management, Bayer AG, and President Pharmaceuticals. Ambrogio will serve on the Pharmaceuticals Executive Committee and be based in Berlin, Germany. Gerd Krueger, who has led the Radiology unit for the past eight years, will work closely with him on a smooth transition before retiring from Bayer after more than forty years of service at the end of March 2024. Nelson Ambrogio, most recently Senior Vice President and General Manager of Bayer’s Oncology Business in the United States, is a global healthcare leader with a career spanning more than 25 years with Bayer. Ambrogio started his career with Schering AG, which Bayer acquired in 2006, and has held commercial leadership roles of increasing responsibility across North and South America, Europe and Asia-Pacific. His broad experience also includes regional and global positions at Bayer’s headquarters. Nelson Ambrogio is married and has four children. "Nelson Ambrogio is a highly accomplished healthcare executive recognized for an exceptional track record of developing and growing businesses by leading diverse teams around the world. His breadth of experience and strong leadership capabilities will be key in continuing to drive our Radiology Business forward," said Stefan Oelrich, Member of the Board of Management, Bayer AG, and President of the company’s Pharmaceuticals Division. "I also want to sincerely thank Gerd Krueger for his dedicated service for the company and for his outstanding leadership in advancing our Radiology Unit to a business with industry-leading growth and profitability, that is driving innovation in its core business as well as in new areas such as Digital. I wish Gerd all the very best in his future endeavors." "As a leader in key Radiology segments and building on a deep medical expertise across a multitude of diagnostic and therapeutic areas, Bayer is driving innovation in medical imaging to address today’s healthcare challenges and advance patient care," said Nelson Ambrogio. "I am excited to join this highly committed team at a time where new exciting paths are taken to deliver true value to radiologists and their teams for the benefit of patients.” About Radiology at Bayer As a true life-science company with a heritage of over 100 years in radiology, Bayer is committed to providing excellence – from innovative products to high-quality services – to support efficient and optimized patient care. Globally, Bayer offers a leading portfolio of contrast media for computed tomography (CT), X-ray, and magnetic resonance imaging (MRI), along with devices for their precise administration, informatics solutions, and a medical imaging platform delivering access to applications, including those enabled by Artificial Intelligence (AI). Bayer’s radiology products generated close to €2bn sales in 2022. Bayer is highly committed to research and development, which includes leveraging AI and driving innovation in medical imaging. Each of these offerings provides effective tools to support radiologists in their mission to deliver treatment-critical answers and a clear direction – from diagnosis to care. About Bayer Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2022, the Group employed around 101,000 people and had sales of 50.7 billion euros. R&D expenses before special items amounted to 6.2 billion euros. For more information, go to www.bayer.com . Find more information at https://pharma.bayer.com/ Follow us on LinkedIn: Bayer | Pharmaceuticals Follow us on Twitter: @BayerPharma Ko (2024-0006) Forward-Looking Statements This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com . The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.

长按扫码预约直播作为小分子药物（化药）和大分子药物（单抗、双抗等）之后的第三代新型药物，小核酸药物具有其独特的优势，受到业界广泛的关注。这些优势包括：特异性强、稳定性高、药效持续时间长、研发周期短和研发成功率高。而且特别值得指出的是，小核酸药物是基于碱基互补配对原则以mRNA为靶点，作用于蛋白表达的上游过程，因此其针对的靶点和适应症的范围更加广泛，可以靶向小分子药物和大分子药物无法靶向或效果不好的靶点。目前全球范围内已经有16款小核酸产品获批上市，包括9款ASO产品、6款siRNA产品、1款aptamer产品。2023年8月22日，诺华靶向PCSK9的超长效降脂药物Inclisiran在华获批上市，基于小核酸药物特性，实现了“半年打一针”的持久疗效，用药频率完爆每月需要注射一至两针的传统PCSK9抗体药物。Inclisiran极有希望成为诺华接下来的销售额支柱，其成功让本就火热的小核酸赛道更加烈火烹油。中国国内方面，最近几个月里，小核酸新药BD交易频频官宣，既有中国本土药企与biotech公司之间的交易，也有中国biotech与跨国药企之间的合作，这意味着中国研发的小核酸新药成功实现出海，获得了全球制药界的认可。为了更好地推动小核酸药物的发展，促进企业之间的交流与合作，我们特别邀请了时安生物创始人杨志伟博士和联合创始人刘楠博士莅临【药时代路演直播间】，向大家介绍时安生物针对重大疾病而开发的具有源头创新潜力的小核酸药物技术平台及管线品种。欢迎大家观看直播！参与讨论还有机会获得新年礼品！01精彩先看（1）具有自主知识产权的行业领先的核酸药物技术平台：* eSAFE化学修饰技术和STORK肝内肝外长效性递送技术平台（2）基于领先的技术平台，成功开发多个新药管线，包括：* 潜在最佳乙肝治愈临床前数据的小核酸联用组合* 潜在降血压领域同类最优小核酸分子……02本期嘉宾杨志伟 博士时安生物 创始人杨志伟博士在北京大学技术物理系获得应用化学学士和放射化学硕士学位后，于美国哥伦比亚大学获得有机化学博士学位，并在哈佛大学从事博士后研究。美国工作的十余年里，杨博士在Schering-Plough（Merck）制药公司从事过多年小分子创新药研究，而后就职于Life Technologies (Thermo Fisher)负责系列核酸递送试剂（Lipofectamine）的研发和生产技术工作。回国后与国内著名小核酸药企合作，主持开发了国内第一个GalNAc肝靶向递送平台，并将其成功应用到多个管线产品中。杨志伟博士曾任北京化工大学生科院教授、江苏省集萃研究员，曾获聘中国科学院深圳先进技术研究院客座教授、苏州大学药学院产业教授等。创新引领，高效务实 | 时安生物创始人杨志伟博士访谈刘楠 博士时安生物 联合创始人刘楠博士在德国弗莱堡大学取得药学博士学位，具有10 余年核酸递送研究经验和6 年以上著名小核酸药物企业的创新药研发经验，在核酸递送技术研发、靶点立项、序列发现及生物评估等领域有扎实的研究基础和丰富的产业开发经验。曾组建过多个核酸药物开发团队，成功开发了全流程的核酸药物技术平台，曾主导的管线产品已有进入临床研究阶段。作为联合创始人于2022 年创立了苏州时安生物技术有限公司，担任总经理，从事核酸创新药的开发。被评为苏州工业园区创业领军人才、苏州市姑苏领军人才、江苏省双创博士。03关于时安生物苏州时安生物技术有限公司于2022年5月在苏州工业园区注册，专注于创新小核酸药开发和产业化。公司获得了姑苏领军、苏州工业园区创业领军称号，拥有2千余平米的实验室，25名全职员工，建成了完整的核酸创新药研发平台。公司申请了15项发明专利，有3款新药进入临床前开发。在北京昌平生命科学园设立了全资子公司，负责注册申报和临床试验。公司在2022年6月获得数千万元天使轮融资，即将完成 pre-A 轮数千万元融资。04报名方式1长按扫码观看直播2参与讨论抽取图书05联系我们Richard Young药时代 BD 副总监如果您对该项目感兴趣，欢迎与我们联系！我们将高效推进您与项目方的合作！Project ID: 小核酸联系人：Richard电话：17821449819微信：DrugTimes_BD邮箱：qi.yang@drugtimes.cn欢迎朋友们走进“药时代直播间”！秉持“聚焦新药研发，荟萃行业精华，分享交流合作，共筑健康天下！”这一宗旨和目标，药时代将推出一系列优质的直播课程，邀请行业专家就新药研发相关的焦点话题做精彩的解读和分享，帮助朋友们学习新知识，掌握新技能，结交新朋友。衷心感谢朋友们长期以来的支持、惠助！我们将竭尽全力，持续不断地为朋友们带来优质、有价值、高品质的内容！往期回顾药时代路演第三期 | 抗体领域龙头企业优质系列双抗对外授权点击这里，发现更多项目！